Given the emerging urgent need to better understand the impact of the COVID-19 pandemic on cancer care, numerous clinical studies have been developed by various organizations in addition to crowdsourcing efforts. Below is a succinct list of current ongoing studies. Only cancer-specific studies are listed, but there are also registries such as the American College of Surgeons (ACS) COVID-19 Registry, which captures data regardless of oncology diagnosis.
This is not a comprehensive list. If you know of any additional COVID-19 clinical studies related to oncology, please share them with Linda Zheng, ACS Cancer Research Program (ACS CRP) Program Coordinator, at firstname.lastname@example.org.
This is a longitudinal, natural history study of COVID-19 in people with cancer to help the National Cancer Institute (NCI) understand how cancer treatment and cancer outcomes are affected by the virus.
Eligibility: Available to all National Clinical Trials Network (NCTN), NCI Community Oncology Research Program (NCORP) and NCI Experimental Therapeutics Clinical Trials Network (ETCTN) sites in the United States via the Cancer Trials Support Unit (CTSU).
This is a companion registry of the American Society of Breast Surgeons (ASBrS) Mastery of Breast Surgery Program to track outcomes and practice patterns of breast surgeons during the COVID-19 pandemic.
Eligibility: Information on breast cancer patients managed during the COVID-19 pandemic is collected through the ASBrS Mastery of Breast Surgery Program.
The American Society of Clinical Oncology (ASCO) Registry is a web-based registry aimed at understanding how the COVID-19 pandemic has impacted the delivery of cancer care and patient outcomes.
Eligibility: Patients with a cancer diagnosis who have confirmed SARS-CoV-2 infection and are being treated in participating institutions in the U.S.
The ASH Research Collaborative’s datahub is a registry of patients who test positive for COVID-19 and have been or are currently being treated for hematologic malignancy. The de-identified data are analyzed on an ongoing basis to provide real-time information via dashboard format.
Eligibility: Health care professionals caring for patient with a hematologic malignancy.
This is a multicenter registry effort to obtain information on patients with cancer who have tested positive for COVID-19. Institutions from the U.S., European Union, Argentina, Canada, and the United Kingdom are participating in this international collaboration.
Eligibility: Participating institutions are listed on the COVID-19 and Cancer Consortium website.